2-methyl-pent-3-yne-1,2-diol | 14848-90-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-methyl-pent-3-yne-1,2-diol
• 英文别名: 2-Methyl-pent-3-in-1,2-diol；2-Methyl-pentin-(3)-diol-(1.2)；2-Methyl-3-pentyne-1,2-diol；2-Methylpent-3-yne-1,2-diol
• CAS: 14848-90-9
• 化学式: C₆H₁₀O₂
• 分子量: 114.144
• InChiKey: GRWBMJHEMSBKFR-UHFFFAOYSA-N

物化性质

• 熔点：
  66-67 °C(Solv: benzene (71-43-2))
• 沸点：
  244.5±20.0 °C(Predicted)
• 密度：
  1.077±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-methyl-pent-3-yne-1,2-diol 在 草酸 作用下， 生成 phenyl-carbamic acid-(2-methyl-pent-1-en-3-ynyl ester)
  参考文献：
  名称：

  Perwejew, Zhurnal Obshchei Khimii, 1949, vol. 19, p. 1306

  摘要：

  DOI：
• 作为产物：
  描述：

  环氧-1,2-甲基-2-戊炔-3 在 盐酸 作用下， 生成 2-methyl-pent-3-yne-1,2-diol
  参考文献：
  名称：

  Perveev,F.Ya.; Shil'nikova,L.N., Journal of Organic Chemistry USSR (English Translation), 1966, vol. 2, p. 1150 - 1153

  摘要：

  DOI：

文献信息

• [EN] THERAPEUTIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET LEURS UTILISATIONS
  申请人：GENENTECH INC

  公开号：WO2016123391A1

  公开（公告）日：2016-08-04

  The present invention relates to compounds of formula (I): and to salts thereof, wherein R1-R6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.

  本发明涉及式(I)的化合物及其盐，其中R1-R6具有规范中定义的任何值，以及其组合物和用途。这些化合物可用作TAF1的抑制剂。还包括包含式(I)的化合物或其药学上可接受的盐的药物组合物，以及在治疗各种TAF1介导的疾病中使用这些化合物和盐的方法。
• C-Quaternary alkynyl glycinols via the Ritter reaction of cobalt complexed alkynyl glycols
  作者：K. Grammatoglou、J. Bolsakova、A. Jirgensons

  DOI：10.1039/c7ra03965d

  日期：——

  glycinols based on the Ritter reaction of acetonitrile with cobalt complexed alkynyl glycols is presented. The reaction is promoted by acids such as H2SO4 or BF3·Et2O to give oxazolines as the reaction products. These are subjected to cobalt complex cleavage in oxidative conditions and subsequent acidic hydrolysis providing amino alcohols. The substrates for the Ritter reaction can be easily assembled

  提出了一种基于乙腈与钴配合的炔二醇的Ritter反应的C-季炔基甘氨酸的新方法。通过酸如H 2 SO 4或BF 3 ·Et 2促进反应O得到恶唑啉作为反应产物。将它们在氧化条件下进行钴配合物裂解，然后进行酸性水解，得到氨基醇。用于Ritter反应的底物可以很容易地组装，以在两个可变位置引入结构多样性。恶唑啉形成的Ritter反应条件与炔烃末端位置上的一系列取代基相容，从而以中等至良好的产率提供恶唑啉。乙二醇反应中心的甲基，羟甲基和甲硅烷氧基甲基取代基具有良好的耐受性，而该位置的苯基不利于反应。
• 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
  申请人：Chau Anh

  公开号：US20090075998A1

  公开（公告）日：2009-03-19

  The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.

  该发明涵盖了式I的新化合物或其药学上可接受的盐。这些化合物是微粒体前列腺素E合酶-1（mPGES-1）酶的抑制剂，因此可用于治疗多种疾病或情况引起的疼痛和/或炎症，如骨关节炎，类风湿性关节炎和急性或慢性疼痛。还包括治疗由mPGES-1酶介导的疾病或情况的方法和制药组合物。
• 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
  申请人：Chau Anh

  公开号：US20070208017A1

  公开（公告）日：2007-09-06

  The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.

  本发明涵盖了公式I的新化合物或其药学上可接受的盐。这些化合物是微粒体前列腺素E合成酶-1（mPGES-1）酶的抑制剂，因此可用于治疗各种疾病或病况引起的疼痛和/或炎症，如骨关节炎、类风湿性关节炎和急性或慢性疼痛。还包括治疗由mPGES-1酶介导的疾病或病况的方法和制药组合物。
• THERAPEUTIC COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20140303164A1

  公开（公告）日：2014-10-09

  Compounds of formula I: or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

  公开了化学式I的化合物或其盐。还公开了包含化学式I化合物的药物组合物，制备化学式I化合物的方法，用于制备化学式I化合物的中间体以及治疗反转录病毒感染的治疗方法，包括由HIV病毒引起的感染。